These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38101816)

  • 21. Mirvetuximab after anaphylaxis to Paclitaxel: A case report.
    Stewart MA; Rives TA; Blanton K; Baldwin L
    Gynecol Oncol Rep; 2024 Aug; 54():101452. PubMed ID: 39076678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.
    Moore KN; Vergote I; Oaknin A; Colombo N; Banerjee S; Oza A; Pautier P; Malek K; Birrer MJ
    Future Oncol; 2018 Jul; 14(17):1669-1678. PubMed ID: 29424243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of an FRα Companion Diagnostic Immunohistochemical Assay for Mirvetuximab Soravtansine.
    James RL; Sisserson T; Cai Z; Dumas ME; Inge LJ; Ranger-Moore J; Mason A; Sloss CM; McArthur K
    Arch Pathol Lab Med; 2024 Nov; 148(11):1226-1233. PubMed ID: 38282564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
    Matulonis UA; Birrer MJ; O'Malley DM; Moore KN; Konner J; Gilbert L; Martin LP; Bauer TM; Oza AM; Malek K; Pinkas J; Kim SK
    Clin Cancer Res; 2019 Mar; 25(6):1727-1736. PubMed ID: 30413525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis.
    Xu K; Wang T; Pan S; He J
    Expert Rev Clin Pharmacol; 2023; 16(11):1141-1152. PubMed ID: 37771164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine.
    Hendershot A; Slabaugh M; Riaz KM; Moore KN; O'Malley DM; Matulonis U; Konecny GE
    Gynecol Oncol Rep; 2023 Jun; 47():101155. PubMed ID: 37102083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Folate Receptor α-Targeted
    Heo GS; Detering L; Luehmann HP; Primeau T; Lee YS; Laforest R; Li S; Stec J; Lim KH; Lockhart AC; Liu Y
    Mol Pharm; 2019 Sep; 16(9):3996-4006. PubMed ID: 31369274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
    Yam C; Rauch GM; Rahman T; Karuturi M; Ravenberg E; White J; Clayborn A; McCarthy P; Abouharb S; Lim B; Litton JK; Ramirez DL; Saleem S; Stec J; Symmans WF; Huo L; Damodaran S; Sun R; Moulder SL
    Invest New Drugs; 2021 Apr; 39(2):509-515. PubMed ID: 32984932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrating antibody drug conjugates in the management of gynecologic cancers.
    Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
    Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
    Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Vergote I; Ponte JF; Birrer MJ
    Future Oncol; 2018 Jan; 14(2):123-136. PubMed ID: 29098867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis.
    Zhu Y; Lin Y; Liu K; Zhu H
    J Gynecol Oncol; 2024 Nov; 35(6):e71. PubMed ID: 38576343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
    Manning-Geist BL; Sullivan MW; Zhou Q; Iasonos A; Selenica P; Stallworth C; Liu YL; Long Roche K; Gordhandas S; Aghajanian C; Chi D; O'Cearbhaill R; Grisham RN; Chui MH
    Gynecol Oncol; 2024 Sep; 188():52-57. PubMed ID: 38941962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer.
    Kokori E; Olatunji G; Komolafe R; Abraham IC; Ukoaka B; Samuel O; Ayodeji A; Ogunbowale I; Ezenwoba C; Aderinto N
    Medicine (Baltimore); 2024 May; 103(20):e38132. PubMed ID: 38758856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite.
    Tu YP; Hanze E; Zhu F; Lagraauw HM; Sloss CM; Method M; Esteves B; Westin EH; Berkenblit A
    Br J Clin Pharmacol; 2024 Feb; 90(2):568-581. PubMed ID: 37872122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen.
    Tu YP; Lagraauw HM; Method M; Wang Y; Hanze E; Li L; Parrott T; Sloss CM; Westin EH
    Br J Clin Pharmacol; 2025 Jan; 91(1):220-231. PubMed ID: 39307840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
    Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-drug conjugates for ovarian cancer: current clinical development.
    Stewart D; Cristea M
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
    Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
    Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Altwerger G; Bonazzoli E; Bellone S; Egawa-Takata T; Menderes G; Pettinella F; Bianchi A; Riccio F; Feinberg J; Zammataro L; Han C; Yadav G; Dugan K; Morneault A; Ponte JF; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Mol Cancer Ther; 2018 May; 17(5):1003-1011. PubMed ID: 29440294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer.
    Zhu F; Tu YP; Sloss C; Wang Y
    Bioanalysis; 2024; 16(21-22):1101-1113. PubMed ID: 39378056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.